The Efficacy of Paxman Scalp Cooling System in Preventing Hair Loss in Breast Cancer Patients Receiving Chemotherapy in Western India - Multi-centre Retrospective Cohort Study

Overview

Journal Indian J Dermatol

Specialty Dermatology

Date 2024 Apr 4

PMID 38572038

Authors

Mangesh Mekha

Ashish Joshi

Vashishth Maniar

Udip Maheshwari

Kshitij Joshi

Pritam Kalaskar

Smit Sheth

Pradip Kendre

Disha Morzaria

Reshma Korgavkar

Chandrashekhar Pethe

Sonal Dhande

Affiliations

Soon will be listed here.

Abstract

Aim: Chemotherapy-induced alopecia (CIA) is the most common side effect of systemic treatment in breast cancer patients. Scalp cooling gained worldwide acceptance in preventing or mitigating CIA in patients undergoing chemotherapy. The objective of this study was to evaluate the efficacy and safety of the Paxman scalp cooling system (PSCS) in Indian breast cancer patients.

Materials And Methods: This is a multi-centre, retrospective-observational study including patients registered from 1 March, 2019 to 30 April, 2021 undergoing chemotherapy for breast cancer by using PSCS. The primary end-point was the incidence of CIA after completing cycles of chemotherapy.

Results: A total of 91 female patients were enrolled in the study, with a median age of 53 years (IQR: 44-62 years). The prevention of alopecia (grade 0 and grade I) was seen in 81%, while more than 50% hair loss (grade 2) was seen in 16.48% after completion of treatment. The univariate analysis results showed that CIA was significantly higher in patients who received anthracyclines (OR: 2.69; 95% CI: 1.04-6.958; = 0.041) and in patients with a post-infusion cooling time of >150 minutes (OR: 8.409; 95% CI: 2.295-30.787; = 0.001). The incidence of grade 2 (>50% hair loss) alopecia was 81.3% in patients <6 weeks and was 18.8% at >6 weeks of start of chemotherapy ( < 0.0001). No adverse events were reported in 71.4% of patients, and the most common adverse event was headache (18.7%).

Conclusion: PSCS is an effective and well-tolerated treatment modality for preventing CIA among breast cancer patients undergoing chemotherapy.

References

Komen M, Van Den Hurk C, Nortier J, van der Ploeg T, Smorenburg C, van der Hoeven J . Patient-reported outcome assessment and objective evaluation of chemotherapy-induced alopecia. Eur J Oncol Nurs. 2018; 33:49-55. DOI: 10.1016/j.ejon.2018.01.001. View

Rosman S . Cancer and stigma: experience of patients with chemotherapy-induced alopecia. Patient Educ Couns. 2004; 52(3):333-9. DOI: 10.1016/S0738-3991(03)00040-5. View

Komen M, Van Den Hurk C, Nortier J, van der Ploeg T, Nieboer P, van der Hoeven J . Prolonging the duration of post-infusion scalp cooling in the prevention of anthracycline-induced alopecia: a randomised trial in patients with breast cancer treated with adjuvant chemotherapy. Support Care Cancer. 2018; 27(5):1919-1925. DOI: 10.1007/s00520-018-4432-6. View

Shah V, Wikramanayake T, DelCanto G, van den Hurk C, Wu S, Lacouture M . Scalp hypothermia as a preventative measure for chemotherapy-induced alopecia: a review of controlled clinical trials. J Eur Acad Dermatol Venereol. 2017; 32(5):720-734. PMC: 8127610. DOI: 10.1111/jdv.14612. View

Bulow J, Friberg L, Gaardsting O, Hansen M . Frontal subcutaneous blood flow, and epi- and subcutaneous temperatures during scalp cooling in normal man. Scand J Clin Lab Invest. 1985; 45(6):505-8. DOI: 10.3109/00365518509155250. View

Bajpai J, Kagwade S, Chandrasekharan A, Dandekar S, Kanan S, Kembhavi Y . "Randomised controlled trial of scalp cooling for the prevention of chemotherapy induced alopecia". Breast. 2019; 49:187-193. PMC: 7375683. DOI: 10.1016/j.breast.2019.12.004. View

Gianotti E, Razzini G, Bini M, Crivellaro C, Righi A, Darecchio S . Scalp Cooling in Daily Clinical Practice for Breast Cancer Patients Undergoing Curative Chemotherapy: A Multicenter Interventional Study. Asia Pac J Oncol Nurs. 2019; 6(3):277-282. PMC: 6518988. DOI: 10.4103/apjon.apjon_4_19. View

Hesketh P, Batchelor D, Golant M, Lyman G, Rhodes N, Yardley D . Chemotherapy-induced alopecia: psychosocial impact and therapeutic approaches. Support Care Cancer. 2004; 12(8):543-9. DOI: 10.1007/s00520-003-0562-5. View

Lemieux J, Provencher L, Perron L, Brisson J, Amireault C, Blanchette C . No effect of scalp cooling on survival among women with breast cancer. Breast Cancer Res Treat. 2014; 149(1):263-8. DOI: 10.1007/s10549-014-3231-0. View

10.

Cigler T, Isseroff D, Fiederlein B, Schneider S, Chuang E, Vahdat L . Efficacy of Scalp Cooling in Preventing Chemotherapy-Induced Alopecia in Breast Cancer Patients Receiving Adjuvant Docetaxel and Cyclophosphamide Chemotherapy. Clin Breast Cancer. 2015; 15(5):332-4. DOI: 10.1016/j.clbc.2015.01.003. View

11.

Nangia J, Wang T, Osborne C, Niravath P, Otte K, Papish S . Effect of a Scalp Cooling Device on Alopecia in Women Undergoing Chemotherapy for Breast Cancer: The SCALP Randomized Clinical Trial. JAMA. 2017; 317(6):596-605. DOI: 10.1001/jama.2016.20939. View

12.

van den Hurk C, Peerbooms M, van de Poll-Franse L, Nortier J, Coebergh J, Breed W . Scalp cooling for hair preservation and associated characteristics in 1411 chemotherapy patients - results of the Dutch Scalp Cooling Registry. Acta Oncol. 2012; 51(4):497-504. DOI: 10.3109/0284186X.2012.658966. View

13.

Kate S, Patil R, Pathan D, Vyavhare R, Joseph S, Baby V . Safety and efficacy of scalp cooling system in preventing chemotherapy induced alopecia - A single center prospective study. Cancer Treat Res Commun. 2020; 26:100280. DOI: 10.1016/j.ctarc.2020.100280. View

14.

Rugo H, Klein P, Melin S, Hurvitz S, Melisko M, Moore A . Association Between Use of a Scalp Cooling Device and Alopecia After Chemotherapy for Breast Cancer. JAMA. 2017; 317(6):606-614. PMC: 5639721. DOI: 10.1001/jama.2016.21038. View

15.

Saad M, Chong F, Bustam A, Ho G, Abdul Malik R, Wan Ishak W . The efficacy and tolerability of scalp cooling in preventing chemotherapy-induced alopecia in patients with breast cancer receiving anthracycline and taxane-based chemotherapy in an Asian setting. Indian J Cancer. 2019; 55(2):157-161. DOI: 10.4103/ijc.IJC_581_17. View

16.

Dilawari A, Gallagher C, Alintah P, Chitalia A, Tiwari S, Paxman R . Does Scalp Cooling Have the Same Efficacy in Black Patients Receiving Chemotherapy for Breast Cancer?. Oncologist. 2021; 26(4):292-e548. PMC: 8018328. DOI: 10.1002/onco.13690. View

17.

Bitto F, Konig A, Phan-Brehm T, Vallbracht T, Koch J, Schinkothe T . EVA-Scalp: Evaluation of Patient Satisfaction with a Scalp Cooling Device to Prevent Chemotherapy-Induced Alopecia in Breast Cancer Patients. Breast Care (Basel). 2020; 15(2):171-177. PMC: 7204843. DOI: 10.1159/000501393. View

18.

Massey C . A multicentre study to determine the efficacy and patient acceptability of the Paxman Scalp Cooler to prevent hair loss in patients receiving chemotherapy. Eur J Oncol Nurs. 2004; 8(2):121-30. DOI: 10.1016/j.ejon.2003.10.006. View

19.

Dunnill C, Al-Tameemi W, Collett A, Haslam I, Georgopoulos N . A Clinical and Biological Guide for Understanding Chemotherapy-Induced Alopecia and Its Prevention. Oncologist. 2017; 23(1):84-96. PMC: 5759815. DOI: 10.1634/theoncologist.2017-0263. View

20.

Fehr M, Welter J, Sell W, Jung R, Felberbaum R . Sensor-controlled scalp cooling to prevent chemotherapy-induced alopecia in female cancer patients. Curr Oncol. 2017; 23(6):e576-e582. PMC: 5176384. DOI: 10.3747/co.23.3200. View